, Volume 125, Issue 7-8, pp 225-226
Date: 22 Mar 2013

Agomelatine-induced hepatotoxicity

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Dear Sir,

Agomelatine (AG) is a melatonin analogue which represents a novel class of antidepressants. It acts as an agonist at melatonin MT(1) and MT(2) receptors and as a specific antagonist at 5-HT(2C) receptors. It is rapidly absorbed orally and mainly metabolised via CYP1A2 hepatic isoenzymes, has no active metabolites and has an elimination half-life of 1–2 h. Although, AG is generally well-tolerated with low adverse event discontinuation rates, it currently requires monitoring of liver function because a small number of patients had raised liver enzyme activities in the trial program [1]. Controlled studies in humans have shown that AG is as effective as the selective serotonin reuptake inhibitor (SSRI) antidepressants paroxetine and sertraline in the treatment of major depression [2]. A review of the research studies conducted to April 2011 concludes that AG should only be considered as an alternative drug for patients who do not respond to or cannot tolerate other antidepressant